Document ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy
|
|
- Ilene Philippa Wilcox
- 5 years ago
- Views:
Transcription
1 Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas Excluding Paediatrics All Clinical Staff To ensure safe use of oral methotrexate Simon Whitworth, Chief Approved Contents Page 1. Introduction 1 2. Background 1 3. Scope 2 4. Prescriber information 2 5. Pharmacy Staff information 3 6. Nursing Staff information 4 7. Document Configuration 5 8. Appendix 1 Summary of information for Junior Doctors 6 Key messages Oral methotrexate MUST only be prescribed by Consultant Staff Oral methotrexate MUST only be prescribed once a week, the remaining six days of the week on the inpatient drug chart MUST be cancelled Patients receiving methotrexate MUST NOT be prescribed trimethoprim or co-trimoxazole (Septrin) preparations, the following wording MUST be added to the drug chart allergy box: Prescribed methotrexate - NOT to be prescribed trimethoprim or cotrimoxazole (Septrin) It is advised that methotrexate is not administered by nursing staff until the prescription has been authorised by the Pharmacy department If methotrexate is temporarily discontinued on admission to hospital, due to clinical reasons, the plan for restarting the methotrexate MUST be clearly stated on the drug chart and in the medical notes 1. Intoduction The purpose of this document is to ensure that all prescribing, dispensing and administration of oral methotrexate within West Suffolk NHS Foundation Trust is in accordance with NPSA Patient Safety Alerts 3 & Background Oral methotrexate is routinely prescribed once weekly in rheumatology, gastroenterology and dermatology. Inadvertent daily prescribing of the weekly dose has lead nationally to a number of avoidable patient deaths. This policy does not cover the use of high dose methotrexate in oncology or haematology treatment regimes. Status: Approved Page 1 of 6
2 3 Scope This policy will apply to all areas of the Trust and all individuals employed by the Trust, including, contractors, voluntary workers, students, locum and agency staff and those holding honorary contracts. 4. Prescriber Information a. Methotrexate may only be prescribed by Consultant Staff b. Information on the risks and benefits of oral methotrexate should be given to the patient before treatment is initiated. Confirmation of the patient s understanding and consent should be sought, baseline tests conducted, monitoring schedule explained. If the treatment is initiated in the outpatient setting a patient-held monitoring booklet should be issued. c. Clear documented arrangements MUST be in place for all patients prescribed methotrexate to ensure that the following are clearly defined for the hospital prescriber, GP and patient: i. clarity of prescribing and monitoring responsibilities; ii. how often blood tests will be conducted and in which location; iii. which clinician will be responsible for receipt and review of the results; iv. who will communicate any necessary dosage changes to the patient and the GP; v. who will record test results on the patient-held monitoring booklet d. All prescribers must avoid the use of as directed in prescribing a specific dose must be applied to each prescription. Bear in mind that patients often understand their dose by the number of tablets they take rather than mg. The required quantity and frequency of dose should be regularly discussed with the patient. e. Repeat (installment) prescribing MUST NOT occur on Trust Outpatient or FP10HP prescription forms. The quantity supplied on the prescription must therefore be appropriate to the clinical needs of the patient but be supplied in one installment f. All staff involved in the care of patients prescribed methotrexate MUST be aware of patients who attend with symptoms such as breathlessness, dry persistent cough, vomiting or diarrhoea, as these can be signs of oral methotrexate toxicity or intolerance. g. It is advised that methotrexate is NOT administered against an inpatient prescription for methotrexate until the prescription has been authorised by a pharmacist, during normal working hours (see 5b-c). It is safer for a dose of methotrexate to be delayed or missed than for a dose to be inadvertently administered. It is recommended that patients own supplies of methotrexate are not used until the prescription has been authorised by a Status: Approved Page 2 of 6
3 The following steps MUST be followed i. All prescriptions must state: Once weekly treatment administer on..day only. ii. All patients prescribed methotrexate MUST have their prescription charts marked by a doctor, nurse or pharmacist: Prescribed methotrexate - NOT to be prescribed trimethoprim or co-trimoxazole (Septrin) in the Drug Reactions / Sensitivities / Allergies section of the drug chart h. If the clinical condition of a patient prescribed methotrexate deteriorates the continued need for methotrexate prescribing should be carefully considered and fully documented in patients notes. If treatment is discontinued this should be fully documented in the medical notes and on the inpatient drug chart and a clear plan documented for potential reintroduction of treatment. The methotrexate prescription should be cancelled on the prescription chart in such a way that it is clear that the patient was prescribed methotrexate but that it is not possible to administer any further doses unless the prescription is rewritten i. It is the prescriber s responsibility to record the correct dosage and frequency on the hospital drug administration chart, and to strike out the six days of the week when a dose must not be administered. j. Handwritten prescriptions and discharge summary information must be complete, legible and include the form, strength, dose and directions in full. 5. Pharmacy Staff Information a. On presentation of a methotrexate out-patient prescription Pharmacy staff will ask to see the patient s monitoring booklet and check if any dose changes have been made since the last prescription issue. b. All prescriptions screened by a pharmacist as appropriate for administration should be clearly marked Authorised and include the pharmacists initials and date and the statement Once weekly treatment administer on....day only. c. All patients prescribed methotrexate MUST have their inpatient prescription charts marked Prescribed methotrexate - NOT to be prescribed trimethoprim or cotrimoxazole (Septrin) in the drug allergy section of the drug chart if not completed by medical staff d. The strength of tablet supplied to the patient must stay consistent to prevent any confusion about the number of tablets they need to take, and the patient s monitoring document and Patient Medication Record should be checked to confirm the previous supply. The West Suffolk NHS Foundation Trust routinely uses only 2.5mg tablets, other than for paediatric patients being treated under specific shared care oncology regimes e. Patients will be informed of their dose in terms of milligrams and the quantity of tablets and weekly frequency. The patient will be given a monitoring booklet if they have not already got one. Status: Approved Page 3 of 6
4 f. If the patient is prescribed methotrexate and folic acid tablets it is essential that the patient is shown how to differentiate between the oral methotrexate and folic acid packaging. If they take both medicines at the same time, they will need to know how to distinguish between them, given that both may be round yellow tablets of similar size. g. Pharmacy staff must be aware of patients who attend with symptoms such as breathlessness, dry persistent cough, vomiting or diarrhoea, as these can be signs of oral methotrexate toxicity or intolerance. Patients reporting these symptoms must be referred back to the prescriber. It is good practice to record of any overthe-counter items supplied to the patient on their out patient prescription form or in their methotrexate treatment booklet. 6. Nursing staff information a. Check the patient s wristband against the medication administration record and the pharmacy labels attached to the medicine s container. Check the patient s name, the medicine, the strength of tablet, the dose and the timing. b. Check that the methotrexate prescription has been marked as authorised by a pharmacist. If this is not the case, withhold the dose and refer to the pharmacy department during normal working hours c. If the prescription is authorised, ask the patient to confirm that the medicine is required. d. Nursing staff must be aware of patients who report symptoms such as breathlessness, dry persistent cough, vomiting or diarrhoea, as these can be signs of oral methotrexate toxicity or intolerance. Patients reporting these symptoms must be referred back to the prescriber. e. Record the medication given on the medication administration record at the time of administering it; a delay in recording it can result in one or more additional doses being given. f. DO NOT administer trimethoprim or co-trimoxazole (Septrin) to patients if methotrexate is prescribed Status: Approved Page 4 of 6
5 Appendix 1 Summary of Methotrexate prescribing information for Medical Staff Treatment initiation a. Information on the risks and benefits of oral methotrexate should be given to the patient before treatment is initiated. Confirmation of the patient s understanding and consent should be sought, baseline tests conducted, monitoring schedule explained. If the treatment is initiated in the outpatient setting a patient-held monitoring booklet should be issued. a. Clear documented arrangements MUST be in place for all patients prescribed methotrexate to ensure that the following are clearly defined for the hospital prescriber, GP and patient: i. Clarity of prescribing and monitoring responsibilities; ii. How often blood tests will be conducted and in which location; iii. Which clinician will be responsible for receipt and review of the results; iv. Who will communicate any necessary dosage changes to the patient and the GP; v. Who will record test results on the patient-held monitoring booklet Prescribing a. Methotrexate may only be prescribed by Consultant Staff b. Junior medical staff may write methotrexate in the drug section of a drug chart, to act as a reminder for the next consultant ward round. This however must not be signed, dated or state a dose. This information will be added by Consultant staff only. c. All prescribers must avoid the use of as directed in prescribing a specific dose must be applied to each prescription. Bear in mind that patients often understand their dose by the number of tablets they take rather than mg. The required quantity and frequency of dose should be regularly discussed with the patient. d. The West Suffolk Hospital routinely uses only methotrexate 2.5mg tablets for adult patients e. All prescriptions must state: Once weekly treatment administer on..day only. f. It is the prescriber s responsibility to record the correct dosage and frequency on the hospital drug administration chart, and to strike out the six days of the week when a dose must not be administered. g. All patients prescribed methotrexate MUST have their prescription charts marked: Prescribed methotrexate - NOT to be prescribed trimethoprim or co-trimoxazole (Septrin) in the Drug Reaction / Sensitivities / Allergies section of the drug chart. h. All staff involved in the care of patients prescribed methotrexate MUST be aware of patients who attend with symptoms such as breathlessness, dry persistent cough, vomiting or diarrhoea, as these can be signs of oral methotrexate toxicity or intolerance. i. It is advised that methotrexate is NOT administered against an inpatient prescription for methotrexate until the prescription has been authorised by a pharmacist, during normal working hours. It is safer for a dose of methotrexate to be delayed or missed than for a dose to be inadvertently administered j. If the clinical condition of a patient prescribed methotrexate deteriorates the continued need for methotrexate prescribing should be carefully considered and fully documented in patients notes. If treatment is discontinued this should be fully documented in the medical notes and on the prescription chart and a clear plan documented for potential reintroduction of treatment. The methotrexate prescription should be cancelled on the prescription chart in such a way that it is clear that the patient was prescribed methotrexate but that it is not possible to administer any further doses unless the prescription is rewritten k. Handwritten prescriptions and discharge summary information must be complete, legible and include the form, strength, dose and directions in full. Status: Approved Page 5 of 6
6 Document Configuration Author(s): Simon Whitworth, Chief Other contributors: Approvals and endorsements: Drugs and Therapeutics Committee (Review ) Drugs and Therapeutics Committee (Review ) Drugs and Therapeutics Committee (Review ) Drugs and Therapeutics Committee (Review ) Operations Group ( ) Medical Staff Committee ( ) Consultation: Nursing directorate Pharmacy department Operations group Drugs and Therapeutics Committee Medical Staff Committee Issue no: 5 File name: H:\Personal\Simon\Policies\Methotrexate\Review Clinical Guideline Jan 2014.doc Supercedes: PP(16)234 Equality Assessed Yes Implementation Via Trust Policy site and inclusion in training programmes Monitoring: (give brief details how this As part of the associated NPSA required audit will be done) programme Other relevant policies/documents & Patient Safety Alert 13, Improving compliance with oral references: methotrexate guidelines, National Patient Safety Agency June 2006 Additional Information: Status: Approved Page 6 of 6
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE
PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE BRIEF OUTLINE OF THIS PROCEDURE This procedure sets out the requirements for prescribing,
More informationPOLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011
POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral
More informationPolicy for the safe use of oral methotrexate
Policy for the safe use of oral methotrexate Policy Checklist Name of Policy: Purpose of Policy: Directorate responsible for Policy Name & Title of Author: Does this meet criteria of a Policy? Staff side
More informationNorth of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines
\ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents
More informationMETHOTREXATE POLICY. Care of Patients who are taking Methotrexate in Low Immunosuppressant Doses (e.g. weekly oral / s/c / or i/m doses)
METHOTREXATE POLICY Care of Patients who are taking Methotrexate in Low Immunosuppressant Doses (e.g. weekly When using this document please ensure that the version you are using is the most up to date
More informationGuidance for Pharmacists on Safe Supply of Oral Methotrexate
Guidance for Pharmacists on Safe Supply of Oral Methotrexate Pharmaceutical Society of Ireland Version 2 January 2015 Contents 1. Introduction 2 2. Methotrexate 2 3. Guidance 2 3.1 Patient Review 2 3.2
More informationWest Suffolk Clinical Commissioning Group (WSCCG) Safety audit for methotrexate prescribing for patients in primary care
West Suffolk Clinical Commissioning Group (WSCCG) Safety audit for methotrexate prescribing for patients in primary care Year 2013-2014 Safety 100% of patients prescribed oral methotrexate should have
More informationProcedure Reviewed By: Narinder Sangha Deputy Chief Pharmacist STANDARD OPERATING PROCEDURE
Written By: Objective By: ed By: To ensure safe and consistent working practice throughout Black Country Partnership Foundation Trust (BCPFT) and to avoid unnecessary harm to patients on lithium therapy
More informationPurpose of the Guideline
Trust Policy and Procedure Substitution of Medicines Policy Document ref. no: PP(17)210 For use in: For use by: For use for: Document owner: Status: All clinical areas Pharmacists and authorised Pharmacy
More informationChemotherapy Training and Assessment Policy. For Medical Prescribers and Pharmacy Verifiers
Chemotherapy Training and Assessment Policy For Medical Prescribers and Pharmacy Verifiers For approvals and version control see Document Management Record on page 6 Doc Ref: AngCN-CCG-C36 Approved and
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationControlled Drugs Accountable Officers Network Scotland Executive Group. Gabapentin and Pregabalin - Frequently Asked Questions
Gabapentin and Pregabalin - Frequently Asked Questions Gabapentin and pregabalin will become Schedule 3 Controlled Drugs in April 2019 NHS Contractor Services Prescribers are legally permitted to be in
More informationIntroduction. Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients)
Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients) Introduction This guideline is designed to provide a framework for patients to administer
More informationEast Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions
East Lancashire Medicines Management Board Shared Care agreement for weekly Methotrexate therapy in long term conditions This shared care agreement outlines the responsibilities for managing the prescribing
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationMedicines Optimisation Strategy
Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic
More informationMEDICINES MANAGEMENT SUB-POLICY 2: PRESCRIPTION WRITING
Edition No: 2.1 ID Number: POLCMM008 Dated: June 2015 Review Date: February 2019 Document ID: Guidelines Document Type: Corporate Directorate: Clinical Support Medicines Category: Services Management Department(s):
More informationThe first stop for professional medicines advice. Community Pharmacy Oral Anticoagulant Safety Audit
Community Pharmacy Oral Anticoagulant Safety Audit This audit has been developed with help and support from the following organisations: Community Pharmacy Patient Safety Group PharmOutcomes Pharmaceutical
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationDisease Modifying Anti-Rheumatic Medications (DMARDS) Monitoring Clinic
Department of Rheumatology Portsmouth Hospitals NHS Trust Disease Modifying Anti-Rheumatic Medications (DMARDS) Monitoring Clinic Patient Information Leaflet Specialist Support This leaflet can be made
More informationNHS Circular: PCA(M)(2011)4 abcdefghijklmnopqrstu TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH SEVERE DISTRESS. Summary
Directorate for Health and Social Care Integration Primary Care NHS Circular: abcdefghijklmnopqrstu Dear Colleague LIST OF DRUGS SUBJECT TO PRESCRIBING TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH
More informationPATIENT SAFETY ALERT
PATIENT SAFETY ALERT PROBLEM: Research in UK and elsewhere has identified a risk to patients from errors occurring during intravenous administration of potassium solutions. Potassium chloride concentrate
More informationSafe Treatment with Oral Methotrexate A Shared Responsibility Demanding a Shared Solution?
Safe Treatment with Oral Methotrexate A Shared Responsibility Demanding a Shared Solution? Tim Delaney, B.Sc.(Pharm.), M.Sc. Mgmt (O.B.), FPSI Programme Lead - Medication Safety Quality & Patient Safety
More information:Connected care. Norfolk and Suffolk NHS Foundation Trust
:Connected care Norfolk and Suffolk NHS Foundation Trust An off-the-shelf Therapeutic Drug Monitoring system developed by the NHS, for the NHS. Clinicians Hospital GP Nurse Practitioner Requesting Doctor
More informationGuidance on Bulk Prescribing for Care Home Residents
Guidance on Bulk Prescribing for Care Home Residents There are many residents in care homes taking medicines when required, which may present problems for the prescriber in determining the quantity to
More informationA themed review of patient safety incidents involving anti-cancer medicines 1 November June 2008
A themed review of patient safety incidents involving anti-cancer medicines 1 November 2003 30 June 2008 October 2010 Executive Summary National Patient Safety Agency 2010. Copyright and other intellectual
More informationNational Neuromyelitis Optica Service
England For Highly Specialised Service National Neuromyelitis Optica Service METHOTREXATE Medication Information This information leaflet is designed to answer common questions patients ask about Methotrexate.
More informationNRT Voucher redemption scheme service specification
NRT Voucher redemption scheme service specification Updated March 2016 Review date March 2018 Page 1 of 7 1. Introduction The NRT voucher scheme is for NHS Fife stop smoking advisors who have been deemed
More informationInitiation of Clozapine Treatment Community Patients
Initiation of Clozapine Treatment Community Patients Who Should Read This Policy Target Audience All clinical staff working in the community N/A N/A Initiation of Clozapine Treatment for Patients in the
More informationWeekly methotrexate tablets
Weekly methotrexate tablets Information to read before you start treatment This information sheet has been given to you to help answer some of the questions you may have about methotrexate. It is in addition
More information1. Intrathecal must never be abbreviated to IT on a prescription form True / False
Appendix 1: Intrathecal SACT Assessment Questions Core General Questions must be completed by all staff. 1. Intrathecal must never be abbreviated to IT on a prescription form 2. Intrathecal SACT must be
More informationMethotrexate. Information for patients. Paediatric Rheumatology. Feedback
Feedback We appreciate and encourage feedback. If you need advice or are concerned about any aspect of care or treatment please speak to a member of staff or contact the Patient Advice and Liaison Service
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationPOLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016
POLICY DOCUMENT Document Title High dose and combination antipsychotic guidance Reference Number n/a Policy Type Prescribing and Treatment Guideline Electronic File/Location Clinical Resources/Pharmacy/Prescribing
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationGuidance for the Network Review of Chemotherapy Errors
Guidance for the Network Review of Chemotherapy Errors For approvals and version control see Document Management Record on page 8 Doc Ref: AngCN-CCG-C31 Approved and published: March 2013 Page 1 of 8 Table
More informationCLINICAL AUDIT. The safe and effective use of. Methotrexate
CLINICAL AUDIT The safe and effective use of Methotrexate Valid to October 2019 bpac nz better medicin e Background Methotrexate is an immunosuppressant used in the treatment of rheumatoid arthritis, severe
More informationMETHOTREXATE (Adults)
Shared Care Guideline Methotrexate (Adults) Contents Introduction:... 1 Contraindications & Warnings:... 2 Interactions:... 3 Adverse Effects:... 3 Responsibilities of the specialist initiating treatment:...
More informationHOSPITAL MEDICINE BECOMING A PHYSICIAN
HOSPITAL MEDICINE BECOMING A PHYSICIAN DR MIKE MASDING Consultant Physician & Diabetologist Poole Hospital NHS Foundation Trust 24 September 2010 Hospital Medicine Becoming a Physician What is a Physician?
More informationLeflunomide Treatment Rheumatology Patient Information Leaflet
Leflunomide Treatment Rheumatology Patient Information Leaflet Originator: Dr K Douglas Date: September 2011 Version: 2 Date for Review: September 2014 DGOH Ref No: DGOH/PIL/00217 Contact numbers If your
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Oral Methotrexate for Rheumatological Conditions Author(s)/Originator(s): (please state author name and department)
More informationURGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU
Primary and Community Care Directorate Pharmacy Division T: 0131-244 2518 F: 0131-244 2375 E: bill.scott@scotland.gsi.gov.uk 25 September 2009 abcdefghijklmnopqrstu = 1. Medical Directors NHS Boards 2.
More informationPHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS
PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In
More informationMethotrexate Methotrexate.indd 1 9/1/16 11:40 AM
Methotrexate 110465 Methotrexate.indd 1 9/1/16 11:40 AM This leaflet only provides information for patients being treated with methotrexate (25mg or less per week). About your medicine Methotrexate is
More informationPatient Group Directions Policy
Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationLRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
More informationPRSB e-discharge summary phase 2 Medications and medical devices information model
PRSB e-discharge summary phase 2 Medications and medical devices information model Purpose This paper provides an information model for medications and medical devices. It is based on the discharge summary
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP
ESCA: All non-biological DMARDs (oral/subcutaneous) and agreement for transferring of DMARD Prescribing & Monitoring to GP Dermatology/ Haematology/ Gastroenterology/ Neurology/ Ophthalmology/ Respiratory/
More informationRheumatology Department Patient Information Leaflet
Methotrexate Rheumatology Department Patient Information Leaflet Please keep this information in a safe place Introduction This leaflet provides information about methotrexate which will be discussed with
More informationCare homes - Homely remedies
Bulletin 72 August 2014 Community Interest Company Care homes - Homely remedies Care home staff have a recognised duty of care to be able to respond to minor symptoms experienced by residents. A homely
More informationMy Passport. Name: Date of birth:
My Passport Name: Date of birth: This passport has been developed to help you keep track of important information related to your liver condition. You can use this passport to record important details
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationThrombosis and Anticoagulation Team. Warfarin. Information for patients, relatives and carers
Thrombosis and Anticoagulation Team Warfarin Information for patients, relatives and carers What is warfarin? Warfarin is an anticoagulant. Anticoagulants are drugs which prevent harmful blood clots forming
More informationGood Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes
Good Practice Guidance on Homely Remedy Policy For Adult Service Users in Care Homes This good practice guidance is intended to be used as a framework for care home managers to adapt when writing their
More informationFalls The Assessment, Prevention and Management of Patient Falls (Adult Services) 1.34
SECTION: 1 PATIENT CARE Including Physical Healthcare POLICY /PROCEDURE: 1.34 NATURE AND SCOPE: SUBJECT (Title): POLICY AND PROCEDURE - TRUST WIDE FALLS: THE ASSESSMENT, PREVENTION AND MANAGEMENT OF PATIENT
More informationconcentrate intravenous solution and other strong potassium solutions
Policy for the use of potassium chloride concentrate intravenous solution and other strong potassium solutions CLINICAL GUIDELINES ID TAG Policy for the use of potassium chloride Title: concentrate intravenous
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationPolicy & Procedures Committee Date: 18 January 2018
Clinical SOP Out-patient Clozapine Initiation Procedure SOP Document Control Summary Status: Replacement supersedes Clozapine Policies and Procedures Version: v1.0 Date: October 2017 Hayley Smart Mo Azar
More informationJylamvo 2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals. Information to minimise the risk of medication error
2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals Information to minimise the risk of medication error NOTE: Special warnings and precautions for use - This oral solution contains
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationMedicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
More informationRTT Exception Report
Appendix 3 RTT Exception Report 1. Purpose To provide a summary of factors impacting on 18 week RTT performance and a revised forecast of red rated performance for Quarter 2 2015/16 for the admitted pathway.
More informationMETHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To
More informationMethotrexate Treatment Rheumatology Patient Information Leaflet
Methotrexate Treatment Rheumatology Patient Information Leaflet Originator: Dr R Klocke, Consultant Rheumatologist and Sr Stephanie Mole, CNS Date: Sept 2011 Version: 1 Date for Review: Sept 2011 DGOH
More informationAim. Managing high risk medicines in primary care. Intended outcomes. Introduction. Risk associated with prescribing
Aim Managing high risk medicines in primary care To increase awareness of high risk medicines and combinations of medicines and to ensure the appropriate prescribing, supply or administration of such in
More informationCurraheen, Co.Cork. Disclaimer: The information contained within this policy is accurate and up-to-date at date of approval.
Curraheen, Co.Cork. SOP Title: Management of Transdermal Patches SOP No: 19 Version number: 2 Date of Re-approval: 28 th July, 2015 Revision due: 28 th July, 2018 Index Code No: CLIN041/SOP NO 19 Disclaimer:
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION
PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION CLASSIFICATION OF DOCUMENT: PURPOSE: Patient Group Direction Document
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationShared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults
Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:
More informationTony Gray Head of Safety and Security. Tony Gray Head of Safety and Security. Contents Section Description Page No.
Health and Safety Policy Practice Guidance Note Latex Sensitivity V04 Date Issued Planned Review Issue 1 Oct 17 Oct 2020 HS-PGN-10 Part of NTW(O)20 Health and Safety Policy Author/Designation Tony Gray
More informationA NEBULISERS AND NEBULISED MEDICATION. Generic Guide for the use of nebulisers and nebulised medication
A NEBULISERS AND NEBULISED MEDICATION Generic Guide for the use of nebulisers and nebulised medication Aim The aim of this guide is to provide a template for those who wish to develop their own nebuliser
More informationProcedure for the prescribing and administration of insulin
Procedure for the prescribing and administration of insulin Author: Lilian Baxendale and Heather Beadle Designation: Clinical Governance Pharmacists Version: Version 3 Date: December 2016 Date Approved:
More informationMEDICINES STANDARD A2: PRESCRIBING METHOTREXATE
MEDICINES STANDARD A2: PRESCRIBING METHOTREXATE Methotrexate has been the subject of a National Patient Safety Agency, (NPSA) Safer Practice Notice Reducing the harm caused by oral methotrexate (issued
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationUnit 204 Assist with the assembly of prescribed items
Element 1 Assemble prescribed 171 172 Element 1 Assemble prescribed Background Assembling prescribed is a complex process. The two main components of this process are labelling and dispensing. It is essential
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine
Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file
More informationNPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE
NPSA SAFER LITHIUM THERAPY GUIDELINES FOR NHS LANARKSHIRE Implementation Date Spring 2013 Review Date Spring 2016 NPSA Safer Lithium Therapy Guidelines for NHS Lanarkshire BACKGROUND On 1 st December 2009
More informationShared Care Guideline
Shared Care Guideline Mercaptopurine inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of mercaptopurine. Dosing: 25mg daily for two weeks, then 1-1.5mg/kg
More informationCare homes - Homely remedies
Bulletin 72 August 2014 Care homes - Homely remedies Care home staff have a recognised duty of care to be able to respond to minor symptoms experienced by residents. A homely remedy is a medicinal product
More informationMedication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016
Medication Safety Patient Safety Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016 1 The patient journey Admission Ward Transfer Ward stay Discharge Medication storage and supply
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationCare Homes - Homely Remedies Protocol
Care Homes - Homely Remedies Protocol A homely remedy is a medicine for the short-term treatment of a minor ailment, such as indigestion, a cough, mild to moderate pain or constipation, and can be obtained
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationIntervention Study 2016 West ISD. Gillian Ritchie Clinical Pharmacist
Intervention Study 2016 West ISD Gillian Ritchie Clinical Pharmacist Introduction Annual data collection Two weeks All Medicines Management Team interventions Details recorded Classified by type Outcomes
More informationCommunity Pharmacy Dementia Audit
Community Pharmacy Dementia Audit Introduction To comply with the NHS contractual requirements associated with the Clinical Governance Essential Service, pharmacy contractors must perform an annual practice
More informationContributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.
Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome
More informationPROOF. Intravenous Adult Community Therapy Team (IV-ACT Team) Intravenous antibiotics in the community
Division of Medicine and Community Services Intravenous Adult Community Therapy Team (IV-ACT Team) Intravenous antibiotics in the community Patient information leaflet for patients receiving (IV) therapy
More informationRegistrar Palliative Medicine
Registrar Palliative Medicine AROHANUI HOSPICE SERVICE TRUST JOB DESCRIPTION RESPONSIBLE TO: Director of Palliative Care, Arohanui Hospice PRIMARY OBJECTIVE: To facilitate the management of patients under
More informationDrug Prescribing. Ravi Menon
Drug Prescribing Ravi Menon Introduction Approximately 7,000 individual drug doses are administered each day in a 'typical' NHS hospital, 70% of which are prescribed by first year graduates and senior
More informationIdentifying and reducing medication errors in mental health
Identifying and reducing medication errors in mental health Hilary Scott Chief Pharmacist South Essex Partnership University NHS Trust with valuable input from Ian Maidment, Senior Lecturer in Clinical
More informationExcellent Care with Compassion
Pain Relief Pain relief for your child following surgery Information for parents and carers Excellent Care with Compassion This leaflet contains information to help you manage your child s pain at home.
More informationCommunity Pharmacy Enhanced Service. Just In Case 4 Core Drugs supply. Stock Holding of Palliative Care Medicines
Community Pharmacy Enhanced Service Just In Case 4 Core Drugs supply Stock Holding of Palliative Care Medicines Parties to the Agreement Provider: Purchaser: NHS Blackpool 1. Service description 1.1 This
More informationADMINISTRATION OF INSULIN
STANDARD OPERATING PROCEDURE ADMINISTRATION OF INSULIN Issue History First issued April 2012 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote the safe administration
More informationSelf-assessment checklist
Self-assessment checklist 1 1 All hospitals should have a fully staffed diabetes inpatient team, made up of the following 1 : consultant. Sufficient diabetes inpatient specialist nurses to run a daily
More information